Pyrrolo[2,1-c][1,4]benzodiazepine-β-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 13, 2008, Pages 3769-3773

  Kamal, Ahmed ^a   Tekumalla, Venkatesh ^a   Raju, P ^a   Naidu, V G M ^a   Diwan, Prakash V ^a   Sistla, Ramakrishna ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Glucuronidase; Glucuronides; ADEPT; PMT; Prodrugs; Pyrrolo 2,1 c 1,4 benzodiazepines; Selective therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PRODRUG; PYRROLLO[2,1 C][1,4]BENZODIAZEPINE BETA GLUCURONIDE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; GENE DIRECTED ENZYME PRODRUG THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CHORIONIC GONADOTROPIN; GAMMA-GLUTAMYL HYDROLASE; GLUCURONIDES; HUMANS; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PRODRUGS; SOLUBILITY; WATER;

EID: 44749093733     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.038     Document Type: Article

References (33)

1. Ferguson M. Drug Resist. Updat. 4 (2001) 225
2. Murray J.C., and Carmichael J. Adv. Drug Deliv. Rev. 17 (1995) 117-127
3. Sherwood R.F. Adv. Drug Deliv. Rev. 22 (1996) 269
4. Bagshawe K.D. Br. J. Cancer 56 (1987) 531
5. Bagshawe K.D. Drug Dev. Res. 34 (1995) 220
6. Denny W.A. Cancer Invest. 22 (2004) 604
7. Springer C.J., and Niculescu-Duvaz I. Adv. Drug Deliv. Rev. 22 (1996) 351
8. Niculescu-Duvaz I., and Springer C.J. Mol. Biotechnol. 30 (2005) 71
9. Bosslet K., Czech J., and Hoffman D. Tumor Target 1 (1995) 45
10. Sinhababu A.K., and Thakker D.R. Adv. Drug Deliv. Rev. 19 (1996) 241
11. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.-P., and Koch M.C. Cancer Res. 58 (1998) 1195
12. Bosslet K., Czech J., and Hoffman D. Tumor Target. 1 (1995) 45
13. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.-P., Koch M., and Monneret C. Cancer Res. 58 (1998) 1195
14. Murdter T., Sperker B., Kivisto K., McClellan M., Fritz P., Friedel G., Linder A., Bosslet K., Toomes H., Diekesmann R., and Kroemer H. Cancer Res. 57 (1997) 2440
15. Angenault S., Thirot S., Schmidt F., Monneret C., Pfeiffer B., and Renard P. Bioorg. Med. Chem. Lett. 13 (2003) 947
16. Albin N., Massaad L., Toussaint C., Mathieu M.-C., Morizet J., Parise O., Gouyette A., and Chabot G.G. Cancer Res. 53 (1993) 3541
17. Kamal A., Rao M.V., Laxman N., Ramesh G., and Reddy G.S.K. Curr. Med. Chem., Anticancer Agents 2 (2002) 215
18. Masterson L.A., Spanswick V.J., Hartley J.A., Begent R.H., Howard P.W., and Thurston D.E. Bioorg. Med. Chem. Lett. 16 (2006) 252
19. Bagshawe K.D. Expert Rev. Anticancer Ther. 6 (2006) 1421
20. Walton M.I., Goddard P., Kelland L.R., Thurston D.E., and Harrap K.R. Cancer Chemother. Pharmacol. 38 (1996) 431
21. Kamal A., Ramesh G., Laxman N., Ramulu P., Srinivas O., Neelima K., Kondapi A.K., Sreenu V.B., and Nagarajaram H.A. J. Med. Chem. 45 (2002) 4679
22. Langley D.R., and Thurston D.E. J. Org. Chem. 52 (1987) 91
23. Courtney S.M., and Thurston D.E. Tetrahedron Lett. 34 (1993) 5327
24. Bose D.S., Jones G.B., and Thurston D.E. Tetrahedron 48 (1992) 751
25. Bollenback G.N., Long J.W., Benjamin D.G., and Lindquist J.A. J. Am. Chem. Soc. 77 (1955) 3312
26. 15: C, 56.28; H, 4.86; N, 5.79%. Found: C, 56.36; H, 4.62; N, 5.98%.
27. 2O as eluent system at 1 ml/min flow. The compound 15b with a retention time of 3.01 min, 4-(hydroxymethyl)-2-nitrophenol spacer 6.35 min and 16b 22.87 min. 15a retention time was 3.13 min and 16a was 22.40 min.
28. Edmondson J.M., Armstrong L.S., and Martinez A.O. J. Tissue Cult. Meth. 11 (1988) 15
29. http://www.atcc.org/common/documents/pdf/30-1010k.pdf.
30. Connors T.A., and Whisson M.E. Nature 210 (1966) 866
31. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.-P., Koch M., and Monneret C. Cancer Res. 58 (1998) 1195
32. Gesson J.P., Jacquesy J.-C., Mondon M., Petit P., Renoux B., Andrianomenjanahary S., Dufat-Trinh Van H., Koch M., Michel S., Tillequin F., Florent J.-C., Monneret C., Bosslet K., Czech J., and Hoffmann D. Anti-Cancer Drug. Res. 9 (1994) 409
33. Goldstein J.A., and Faletto M.B. Environ. Health Perspect. 100 (1993) 169